Seek and destroy: relating cancer drivers to therapies

Abstract

In this issue of Cancer Cell, Rubio-Perez and colleagues present an in silico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.